U.S., May 7 -- ClinicalTrials.gov registry received information related to the study (NCT06959368) titled 'Vonoprazan Evaluation Compared to Standard Triple Therapy in Helicobacter Pylori eRadication' on April 28.
Brief Summary: Helicobacter pylori (H Pylori) infection is associated with functional dyspepsia, peptic ulcer disease, atrophy and gastric cancer. The bacterium has been classified as grade I carcinogen by the WHO in 1994(1). Based on the clinical and microbiological data it is now well known to be the strongest risk factor for developing intestinal type and diffuse type of adenocarcinoma(2-4). While testing and treating asymptomatic persons is a grey area, it is now recommended to rule out H. pylori in un-investigated dyspepsia ...